Reimagine Cancer Care: Insights That Drive Smarter Decisions - Prime Therapeutics
Reimagine Cancer Care: Insights That Drive Smarter Decisions
Explore the latest oncology trends, payer strategies and pipeline updates shaping the future of managed care.
The Fall 2025 Prime Therapeutics Report delivers a comprehensive look at the evolving oncology landscape—from rising cancer rates in younger populations to the expanding role of radiopharmaceuticals and cellular therapies.
Inside this issue:
- Radiopharmaceuticals: Utilization trends, payer strategies and pipeline forecasts
- Early-onset cancer: Incidence spikes, screening shifts and survivorship planning
- Cellular therapy: First approvals for solid tumors and payer cost management
- Bispecific antibodies: Tocilizumab prophylaxis and toxicity management
- Accelerated approvals: Traditional approvals, withdrawals and payer impact
- Multiple myeloma: Brief update, new approvals and pipeline outlook
Whether you're a managed care executive, clinician or pharmacy leader, this report offers actionable insights to help you navigate high-cost therapies, optimize site-of-care strategies and improve patient outcomes.
About Prime Therapeutics
Prime Therapeutics LLC (Prime) is a diversified pharmacy solutions organization. We offer innovative pharmacy benefit management, specialty and medical drug management, and state government solutions to millions of people across the country. At Prime, we’re reimagining pharmacy solutions to provide the care we’d want for our loved ones. We challenge the way it’s always been done to develop intelligently designed solutions that deliver savings, simplicity and support to help people achieve better health. For more information, visit us at PrimeTherapeutics.com or follow us on LinkedIn.